Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 7Lymphoid 5Plasma cell 4Myeloid 3Dermatologic 3Sarcoma 2Gastrointestinal 2Thoracic 1Head & Neck 1Genitourinary 1Classical hematology 1Breast 1

Conditions

Rectal Neoplasms 2Colonic Neoplasms 2Colorectal Neoplasms 1

Interventions

Fluorouracil 286Oxaliplatin 274Gemcitabine 222Capecitabine 221Leucovorin 219Bevacizumab 200Irinotecan 170pembrolizumab 140Cisplatin 132Cetuximab 111Radiotherapy 109Sorafenib 75Nivolumab 75130-nm albumin-bound paclitaxel 64Paclitaxel 63Albumin-Bound Paclitaxel 63Docetaxel 61Erlotinib Hydrochloride 57Panitumumab 56Radiosurgery 47Folfox protocol 46regorafenib 45Sunitinib 40Radiation 39Magnetic Resonance Spectroscopy 38durvalumab 33Surgical Procedures, Operative 33Trastuzumab 32Ramucirumab 32Cyclophosphamide 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × In Situ Hybridization, Fluorescence × Gastrointestinal × Clear all
NCT00655499 2021-09-21

PIMABI

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Completed
65 enrolled 18 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00551421 2015-03-31

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
17 enrolled 7 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡